Show simple item record

dc.creatorAnifandis G., Michopoulos A., Daponte A., Chatzimeletiou K., Simopoulou M., Messini C.I., Polyzos N.P., Vassiou K., Dafopoulos K., Goulis D.G.en
dc.date.accessioned2023-01-31T07:31:56Z
dc.date.available2023-01-31T07:31:56Z
dc.date.issued2019
dc.identifier10.1080/19396368.2018.1516000
dc.identifier.issn19396368
dc.identifier.urihttp://hdl.handle.net/11615/70633
dc.description.abstractInfertile couples with low oocyte yield in combination with abnormal semen parameters may experience intra-cytoplasmic sperm injection (ICSI) failure. An established factor associated with ICSI failure is oocyte activation deficiency (AOD). The latter originates from seminal contributors, such as phospholipase C-zeta (PLCζ) that is not adequate to produce calcium (Ca 2+ ) oscillations for oocyte activation. Apart from this natural activator, other stimulants, such as A23187, ionomycin, strontium chloride or even electric pulses, have been used in embryological laboratories to overcome AOD and ICSI failure. The aim of the present narrative review is to discuss the role of Ca +2 oscillations in oocyte activation and summarize the evidence concerning the use of oocyte activators as agents for artificial oocyte activation (AOA). Studies in humans and animals have emerged many physiological, pathophysiological and ethical aspects of AOA. In conclusion, in mammalian eggs, the cytosolic Ca +2 oscillations derive from a periodic release of Ca +2 from intracellular pools. PLCζ, as well as artificial stimulants, have been used to produce Ca +2 oscillations for AOA. As the latter may increase the risk of epigenetic induced malformations, further studies are required to clarify whether AOA constitutes an effective and safe method to overcome ICSI failure. Abbreviations: AOA: artificial oocyte activation; AOD: oocyte activation deficiency; Ca +2 : Calcium; CAMKII: Ca +2 /calmodulin-dependent protein kinase II; CICR: calcium-induced calcium-release; DAG: diacylglycerol; GM-CSF: granulocyte-macrophage colony-stimulating factor; ICSI: intra-cytoplasmic sperm injection; InsP 3 R: inositol-trisphosphate receptor; IP 3 : inositol 1,4,5-trisphosphate; IVF: in vitro fertilization; MAP: mitogen-activated protein; MII: metaphase II; NADP: nicotinic acid adenine dinucleotide phosphate; NO: nitric oxide; PAWP: post-acrosomal WW-binding domain protein; PIP 2 : phosphatidylinositol 4,5-bisphosphate; PLC: phospholipase C; PLCζ: phospholipase C-zeta; SOAFs: spermatozoon-released oocyte-activating factors; Sr +2 : strontium; TFF: total fertilization failure. © 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group.en
dc.language.isoenen
dc.sourceSystems Biology in Reproductive Medicineen
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85053435001&doi=10.1080%2f19396368.2018.1516000&partnerID=40&md5=d2886bac499dcaa99e6a14facd851908
dc.subjectcalcimycinen
dc.subjectcalcium ionen
dc.subjectionomycinen
dc.subjectpawp proteinen
dc.subjectplc gamma proteinen
dc.subjectproteinen
dc.subjectstrontium chlorideen
dc.subjectunclassified drugen
dc.subjectcalcium ionophoreen
dc.subjectcarrier proteinen
dc.subjectphosphatidylinositol 4,5 bisphosphate phosphodiesteraseen
dc.subjectPLCZ1 protein, humanen
dc.subjectseminal plasma proteinen
dc.subjectWBP2NL protein, humanen
dc.subjectcalcium signalingen
dc.subjectcell activationen
dc.subjecthumanen
dc.subjectintracytoplasmic sperm injectionen
dc.subjectmedical ethicsen
dc.subjectnonhumanen
dc.subjectoocyteen
dc.subjectpathophysiologyen
dc.subjectphysiologyen
dc.subjectpriority journalen
dc.subjectReviewen
dc.subjectanimalen
dc.subjectcalcium signalingen
dc.subjectintracytoplasmic sperm injectionen
dc.subjectoocyteen
dc.subjecttreatment failureen
dc.subjectAnimalsen
dc.subjectCalcium Ionophoresen
dc.subjectCalcium Signalingen
dc.subjectCarrier Proteinsen
dc.subjectHumansen
dc.subjectOocytesen
dc.subjectPhosphoinositide Phospholipase Cen
dc.subjectSeminal Plasma Proteinsen
dc.subjectSperm Injections, Intracytoplasmicen
dc.subjectTreatment Failureen
dc.subjectTaylor and Francis Ltden
dc.titleArtificial oocyte activation: physiological, pathophysiological and ethical aspectsen
dc.typeotheren


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record